Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth


      News provided by

      Shire plc

      28 Oct, 2011, 11:00 GMT

      Share this article

      Share this article


      DUBLIN, October 28, 2011 /PRNewswire/ --

      Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.

          Financial Highlights             Q3 2011(1)
                                            
          Product sales             $1,018 million    +28%
          Total revenues            $1,086 million    +24%
       
          Non GAAP operating income   $341 million    +15%
          US GAAP operating income    $255 million    +64%
          Non GAAP diluted earnings
          per ADS                            $1.28    +10%
          US GAAP diluted earnings
          per ADS                            $1.02    +96%
          Non GAAP cash generation    $296 million     +9%
          Non GAAP free cash flow     $138 million    +56%
          US GAAP net cash provided
          by operating activities     $179 million    +26%
      


      (1)    Percentages compare to equivalent period in 2010.

      The Non GAAP financial measures included within this release are explained on page 24, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 23.

      Angus Russell, Chief Executive Officer, commented:

      "Shire has delivered another strong set of quarterly results. Total product sales were up 28% to $1,018 million, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter. We're on track to deliver significant 2011 earnings growth.

      Sales of our rare disease treatments were very strong: with VPRIV up 31% and REPLAGAL up 40% versus the same quarter in 2010. FIRAZYR, our self-administered treatment for acute attacks of Hereditary Angioedema, was approved by the FDA in August and launched just a few weeks ago; initial demand from patients has been positive. This week we have also initiated a rolling Biologics License Application for REPLAGAL in the US, designated Fast Track by the FDA.

      The US ADHD market continues to grow and with a strong 'back to school' season, our portfolio of treatments has gained share. VYVANSE sales were up 32% and INTUNIV sales grew 50%.

      The investment in our product portfolio is already delivering benefits and we believe our R&D pipeline will provide important therapies to patients around the world. In addition to initiating Phase 3 clinical trials for VYVANSE as adjunctive therapy in Major Depressive Disorder (MDD), we're releasing highlights of exploratory data showing that cognition and executive function were improved in patients with MDD taking VYVANSE as adjunctive therapy. We've also released positive new clinical data related to our Phase 3 European ADHD clinical program. Overall, we've increased investment in our R&D programs by 21% compared to Q3 2010, and still generated good earnings growth and strong cashflows.

      Over the course of the year we've seen market expectations for Shire's 2011 earnings rise, with further increases in the last quarter. After these good third quarter results, and after taking account of the lower royalty income that we will be recording in future periods, we remain on track to meet these increased expectations. We anticipate that this will be another very good year for Shire as we deliver strong sales and continue our investment program for sustained future growth."

      FINANCIAL SUMMARY

      Third Quarter 2011 Unaudited Results

                                  Q3 2011                       Q3 2010
                                             Non                          Non
                      US GAAP   Adjustments  GAAP  US GAAP  Adjustments   GAAP
                           $M        $M       $M       $M          $M       $M
          Total
          revenues      1,086         -    1,086      874           -       874
          Operating
          income          255        86      341      156         142       298
       
          Diluted
          earnings
          per ADS       $1.02     $0.26    $1.28    $0.52       $0.64     $1.16
      


      • Product sales were up 28% to $1,018 million (Q3 2010: $794 million) as our existing products continued to demonstrate strong growth even when compared to the very good performance in Q3 2010. In Q3 2011 we recognized the first full quarter of DERMAGRAFT® sales which contributed six percentage points to product sales growth. On a constant exchange rate ("CER") basis, which is a Non GAAP measure, product sales were up 25%.

      Product sales in the quarter benefited from higher ADDERALL XR® sales, in part due to significantly lower sales deductions following a lowering of the estimate of inventory in the US retail pipeline.

      • The strong product sales growth more than offset declines in 3TC® and ZEFFIX® royalties, both of which are now affected by the disagreement with GlaxoSmithKline ("GSK"), to give growth in total revenues of 24%, to $1,086 million in the quarter (Q3 2010: $874 million).

      • As expected, research and development ("R&D") was up 21% on a Non GAAP basis compared to Q3 2010, as we continue to invest in both early and late stage programs across our business to enable us to deliver future growth. On a US GAAP basis, R&D expenditure increased 2% compared to Q3 2010.

      • Non GAAP operating income was up 15% to $341 million (Q3 2010: $298 million). As expected, Non GAAP operating expenses increased at broadly the same rate as the increase in product sales compared to Q3 2010. This increase was due to increased investment in our R&D program and higher selling, general and administrative ("SG&A") expenditure as we absorb the operating costs of Advanced BioHealing Inc. ("ABH") and Movetis, neither of which were incurred in Q3 2010, in addition to supporting product launches and our continued growth.

      Non GAAP diluted earnings per American Depositary Share ("ADS") were up 10% to $1.28 (Q3 2010: $1.16), due to the higher Non GAAP operating income, partially offset by higher Non GAAP Other Expenses.

      • On a US GAAP basis, operating income was up 64% to $255 million (Q3 2010: $156 million). Q3 2010 included the up-front payment to Acceleron Pharma Inc. ("Acceleron") and impairment charges relating to the divestment of DAYTRANA®.

      US GAAP diluted earnings per ADS were up 96% to $1.02 (Q3 2010: $0.52), due to both higher US GAAP operating and Other Income (which for US GAAP includes the gain on disposal of shares held in Vertex Pharmaceuticals Inc. ("Vertex")).

      • Cash generation, a Non GAAP measure, was up 9% to $296 million (Q3 2010: $271 million). Higher cash receipts from gross product sales were partially offset by lower royalty receipts and higher cash payments on the increased investment in R&D and SG&A, as well as higher sales deduction payments in the quarter.

      Free cash flow, also a Non GAAP measure, was up 56% to $138 million compared to Q3 2010.  Free cash flow in Q3 2010 ($89 million) included the impact of the $45 million upfront payment to Acceleron.

      On a US GAAP basis, net cash provided by operating activities was $179 million (Q3 2010: $142 million).

      2011 OUTLOOK


      After these third quarter results we remain on track to meet current market expectations for 2011 earnings.

      For the full year we expect to see continued strong product sales growth. Royalty and other revenues combined are expected to continue to decline but now by around 17% for the full year (previous expectation, 10%) compared to 2010. Taken together, we expect year on year growth in total revenues in the second half to be broadly in line with the rate of 22% seen in the first half.

      We continue to expect gross margins to be marginally diluted in the second half as a result of the inclusion of ABH, although gross margins for the full year should be in line with those recorded in 2010.

      As previously indicated, we have significant opportunities for future growth. During the year we have initiated a program of investment to advance our pipeline and continue the international expansion of our portfolio. We continue to expect that combined R&D and SG&A for the full year will be around 20% higher than 2010, reflecting this investment program and the inclusion of ABH's cost base in 2011.

      We anticipate our Non GAAP effective tax rate to be between 22 and 24% for the full year.

      Overall, the operational leverage we expect to achieve for the full year will drive significant earnings growth in 2011, and we reiterate our aspirational growth targets.

      THIRD QUARTER 2011 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS


      Products


      FIRAZYR® - for the treatment of acute attacks of Hereditary Angioedema ("HAE") in adults

      • On August 25, 2011 Shire announced that the U.S. Food and Drug Administration ("FDA") had granted marketing approval for FIRAZYR in the US for treatment of acute attacks of HAE in adults 18 years of age and older. After injection training, patients may self-administer FIRAZYR, the first and only self-administered subcutaneous treatment for acute HAE. FIRAZYR has orphan drug designation status in Europe and the US for the treatment of acute HAE.

      VPRIV® and REPLAGAL® Manufacturing Update

      • Shire has completed process validation runs for VPRIV at its new Lexington manufacturing facility and intends to file for regulatory approvals starting in November 2011. Approval for the manufacture of VPRIV at the Lexington facility is anticipated in early 2012 and will significantly increase Shire's manufacturing capacity for VPRIV. In addition, this approval will release further capacity for the manufacturing of REPLAGAL at Shire's Alewife facility where both VPRIV and REPLAGAL are currently manufactured.

      VPRIV - for the treatment of Type 1 Gaucher disease

      • Shire's continued focus remains on providing patients with long term, uninterrupted treatment with VPRIV, with approximately 1,200 patients worldwide currently on treatment. Shire has experienced an increase in demand for VPRIV following the recent announcement of CEREZYME® shortages in the US and other countries. Shire can accommodate a limited number of additional patients prior to approval of the Lexington facility. Shire will carefully monitor and seek to manage this increased demand until the Lexington facility is approved.  

      REPLAGAL - for the treatment of Fabry disease

      • Earlier this week, Shire initiated a rolling Biologics License Application ("BLA") for REPLAGAL in the US, designated Fast Track by the FDA. Shire plans to submit the final BLA sections in November 2011 and will request Priority Review of this submission in response to the continuing supply shortage of FABRAZYME®. In 2010 Shire withdrew its BLA in order to gather additional clinical data for REPLAGAL. These data, including data from Shire's ongoing US Treatment Protocol, have now been evaluated and will be included in the new filing.

      Shire is continuing to experience strong demand for REPLAGAL from both patients new to treatment and patients switching from FABRAZYME. Approximately 2,800 patients worldwide are currently receiving REPLAGAL and Shire can accommodate a modest number of new patients per month prior to approval of the Lexington facility. Shire will continue to carefully monitor the addition of new patients to ensure that we can provide patients with uninterrupted long term supply of REPLAGAL at the recommended dose and frequency.

      Pipeline


      DERMAGRAFT - for the treatment of Venous Leg Ulcers ("VLU")

      • On August 24, 2011 Shire announced its preliminary analysis of the top-line results from ABH's Phase 3 pivotal trial of DERMAGRAFT in subjects with VLU. The international pivotal trial was designed as a prospective, multicenter, randomized, controlled clinical study to assess the product's safety and efficacy in the promotion of healing VLU. The preliminary analysis of the data was that the trial did not meet the primary endpoint mutually agreed with the FDA and European Medicine Agency.

      VYVANSE® - for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")

      • On October 21, 2011 Shire reported positive top line results of the first European Phase 3 study of once-daily lisdexamfetamine dimesylate ("LDX") in children and adolescents aged 6 to 17 years with ADHD. The study, conducted at 48 sites across Europe, demonstrated that a once-daily morning dose of LDX resulted in positive efficacy results on the primary as well as key secondary endpoints compared to placebo, and a safety profile consistent with the known effects of amphetamine treatment and previous LDX trials. In the study, patients were randomized to receive LDX, osmotic-controlled extended-release methylphenidate ("OROS-MPH"; marketed as CONCERTA® and CONCERTA XL® by Johnson & Johnson) or placebo, over a period of seven weeks. The CONCERTA arm was included in order to provide data versus the current European standard of care as it is often required for approval and to support appropriate reimbursement. The primary measure was the change in total score of the ADHD-RS-IV of LDX versus placebo with OROS-MPH included as an active control.

      VYVANSE - for the treatment of inadequate response in Major Depressive Disorder ("MDD")

      • Today, in the live conference call for investors, Shire will present the highlights of new data from an exploratory study for VYVANSE as adjunctive therapy in adults with significant cognitive impairments with partially or fully remitted MDD. This study met its primary and secondary endpoints.

      • A Phase 3 clinical trial program to assess the efficacy and safety of VYVANSE as adjunctive therapy in patients with MDD has been initiated.

      BOARD CHANGES

      Mr Patrick Langlois, who has been a member of Shire's Board of Directors for 6 years, will be stepping down from the Board and from the Company's Audit, Compliance & Risk Committee and its Remuneration Committee on the expiry of his current term of office on November 10, 2011. Matthew Emmens, Chairman of Shire, said "We thank Patrick for his contribution to Shire over the past few years".

      ADDITIONAL INFORMATION

      The following additional information is included in this press release:

                                            Page
          Overview of Third
          Quarter 2011 Financial
          Results                             6
          Financial Information              10
          Non GAAP Reconciliations           19
          Safe Harbor Statement              23
          Explanation of Non GAAP
          Measures                           24
          Trademarks                         25
      


      OVERVIEW OF THIRD QUARTER 2011 FINANCIAL RESULTS

      1.    Product sales

      For the three months to September 30, 2011 product sales increased by 28% to $1,018.4 million (Q3 2010: $794.3 million) and represented 94% of total revenues (Q3 2010: 91%).

      Product Highlights

                                                                       US Exit
                                                                       Market
                                             Year on year growth      Share(1)
                               Sales $M   Sales       CER     US Rx(1)
          Product                      
          VYVANSE               199.7      +32%       +32%       +20%       16%
          ADDERALL XR           149.9      +50%       +50%        +8%        7%
          REPLAGAL              129.0      +40%       +31%       n/a(3)    n/a(3)
          ELAPRASE(R)           109.6      +13%        +7%       n/a(2)    n/a(2)
          LIALDA/MEZAVANT(R)     89.7      +18%       +17%        +7%       21%
          VPRIV                  64.6      +31%       +27%       n/a(2)    n/a(2)
          INTUNIV(R)             56.1      +50%       +50%       +59%        4%
          PENTASA(R)             55.9       -2%        -2%        -4%       15%
          DERMAGRAFT             50.0       n/a        n/a       n/a(2)    n/a(2)
          FOSRENOL(R)            40.5      -10%       -14%       -17%        5%
          FIRAZYR                 7.2     +148%      +129%       n/a(2)    n/a(2)
          RESOLOR(R)              1.5       n/a        n/a       n/a(3)    n/a(3)
          OTHER                  64.7      -25%(4)    -29%       n/a       n/a
          Total product sales 1,018.4      +28%       +25%
      


      (1)      Data provided by IMS Health National Prescription Audit ("IMS NPA"). Exit market share represents the average monthly US market share in the month ended September 30, 2011.

      (2)          IMS NPA Data not available.

      (3)    Not sold in the US in Q3 2011.

      (4)    Q3 2010 included DAYTRANA product sales of $14.7 million.

      VYVANSE - ADHD

      The growth in VYVANSE product sales resulted from higher prescription demand, due to growth in the US ADHD market and increases to VYVANSE's share of that market, in addition to the effect of a price increase taken since Q3 2010. These positive factors were partially offset by higher sales deductions in Q3 2011 compared to Q3 2010.

      ADDERALL XR - ADHD

      Product sales for ADDERALL XR increased due to higher prescription demand, due primarily to growth in the US ADHD market and lower sales deductions. Sales deductions as a percentage of gross product sales (47% for the quarter) were significantly lower than Q3 2010 (60%) and the first half of 2011 (61%), due primarily to a lowering of the estimate of inventory in the US retail pipeline, and the related sales deduction reserve. We expect that sales deductions will be between 60-65% of gross product sales for the fourth quarter.

      REPLAGAL - Fabry disease

      The growth in REPLAGAL product sales was driven by the treatment of new patients, being both naïve patients and switches from FABRAZYME. Reported REPLAGAL sales also benefited from favorable foreign exchange, due to the weaker US dollar in Q3 2011 compared to Q3 2010.

      ELAPRASE- Hunter syndrome

      Product sales for ELAPRASE increased as a result of increased patients on therapy across all regions in which ELAPRASE is sold. Reported ELAPRASE sales also benefited from favorable foreign exchange.

      LIALDA/MEZAVANT - Ulcerative colitis

      LIALDA/MEZAVANT product sales continued to grow in Q3 2011, driven primarily by increased US prescription demand due to higher US market share and the effect of price increases taken since Q3 2010, partially offset by customer destocking in Q3 2011.

      VPRIV - Gaucher disease

      VPRIV product sales growth was driven by the treatment of new patients, being both naïve patients and switches from CEREZYME. Reported VPRIV sales also benefited from favorable foreign exchange.

      INTUNIV - ADHD

      INTUNIV product sales were up 50% compared to Q3 2010 primarily driven by strong growth in prescription demand compared to Q3 2010. The growth in product sales was marginally less than the increase in US prescription demand due to de-stocking in Q3 2011 compared to stocking in Q3 2010 and slightly higher sales deductions as a percentage of product sales in Q3 2011.

      PENTASA - Ulcerative colitis

      The decrease in PENTASA product sales was driven by a decrease in US prescription demand as well as higher destocking in Q3 2011 as compared to Q3 2010. This decrease was partially offset by price increases and lower sales deductions as compared to Q3 2010.

      DERMAGRAFT - Diabetic Foot Ulcers ("DFU")

      DERMAGRAFT(1) continues to see strong revenue growth in the US, up 27% compared to Q3 2010. The growth resulted from a combination of an expanding US diabetic population, continued adoption of DERMAGRAFT as an efficacious, cost-effective treatment for DFU, and the continued addition of sales representatives to market the product.

      (1) Shire acquired DERMAGRAFT through its acquisition of ABH in Q2 2011.

      FOSRENOL - Hyperphosphatemia

      Product sales of FOSRENOL decreased due to the combined effect of lower US prescription demand resulting from a fall in market share and higher sales deductions in Q3 2011 as compared to Q3 2010.

      2.    Royalties

                                                               Year on year
                                                                  growth
                                Royalties to
          Product                 Shire $M          Royalties             CER
       
          ADDERALL XR   1.00        22.9               27%                27%
          3TC and
          ZEFFIX        1.00        17.3              -57%               -58%
          FOSRENOL      1.00        10.9               56%                56%
          Other         1.00        11.7                7%                 0%
          Total         1.00        62.8              -18%               -19%
      


      Royalty income decreased in Q3 2011 compared to Q3 2010 as higher royalties on ADDERALL XR and FOSRENOL were more than offset by lower royalties from 3TC and ZEFFIX.

      Royalty income from 3TC and ZEFFIX continues to be adversely impacted by increased competition from other products. Additionally, in Q3 2011 Shire has continued to not recognize royalty income for 3TC for certain territories due to a disagreement between GSK and Shire about how the relevant royalty rate should be applied given the expiry dates of certain patents. In Q3 2011 this disagreement extended to ZEFFIX, and accordingly Shire has not recognized ZEFFIX royalty income for the affected territories. GSK and Shire continue to hold discussions in order to clarify this issue.

      3.    Financial details

      Cost of product sales

                                           % of                 % of
                                        product              product
                            Q3 2011       sales  Q3 2010       sales
                                 $M                   $M
          Cost of product
          sales (US GAAP)     166.5         16%    112.7         14%
          Unwind of
          DERMAGRAFT
          inventory fair
          value step-up on
          acquisition          (9.0)                   -
          Transfer of
          manufacturing
          from Owings Mills    (3.4)                (7.3)
          Depreciation         (8.6)                (2.3)
          Cost of product
          sales (Non GAAP)    145.5         14%    103.1         13%
      


      Non GAAP cost of product sales as a percentage of product sales increased in Q3 2011 compared to the same period in 2010 due to the inclusion of DERMAGRAFT and the impact of a $10.0 million inventory write down of expired ELAPRASE unpurified bulk material, which was not prioritised for purification as capacity was directed towards meeting demand for REPLAGAL and VPRIV.

      US GAAP cost of product sales as a percentage of product sales was two percentage points higher than the same period in 2010 due to the ELAPRASE write down and the inclusion of DERMAGRAFT, including the fair value adjustment for DERMAGRAFT inventories in Q3 2011.

      R&D

                                      % of              % of
                                   product           product
                          Q3 2011    sales  Q3 2010    sales
                               $M                $M
      
          R&D (US GAAP)     201.5      20%    197.9      25%
          Impairment of
          intangible
          assets            (16.0)                -
          Up-front
          payment to
          Acceleron             -             (45.0)
          Depreciation       (5.6)             (4.4)
          R&D (Non GAAP)    179.9      18%    148.5      19%
      


      Non GAAP R&D was up $31.4 million, or 21%, due to growing investment in a number of targeted R&D programs, including Sanfilippo A and other early stage development programs, in addition to increased investment in new uses for VYVANSE. Non GAAP R&D in Q3 2011 also included expenditure on the development programs acquired with Movetis and ABH, neither of which were incurred in Q3 2010.

      On a US GAAP basis, R&D costs in Q3 2011 also include an intangible asset impairment charge, and Q3 2010 included the up-front payment to Acceleron.

      SG&A

                                      % of              % of
                                   product           product
                          Q3 2011    sales  Q3 2010    sales
                               $M                $M
          SG&A (US GAAP)    452.1      44%    392.4      49%
          Intangible
          asset
          amortization      (46.4)            (31.2)
          Impairment of
          intangible
          assets                -             (42.7)
          Depreciation      (16.7)            (16.1)
          SG&A (Non GAAP)   389.0      38%    302.4      38%
       
      


      Non GAAP SG&A increased by $86.6 million, or 29% as we continue to support the growth of our existing and newly launched products. Non GAAP SG&A in Q3 2011 included expenditure for ABH and Movetis which was not incurred in the same period in 2010.

      On a US GAAP basis, SG&A costs in Q3 2010 included an impairment charge to write down the DAYTRANA intangible asset to its fair value less costs to sell following agreement to divest the product to Noven Pharmaceuticals Inc. ("Noven").

      Reorganization costs

      For the three months to September 30, 2011 Shire recorded reorganization costs of $5.0 million (Q3 2010: $9.7 million) relating to the transfer of manufacturing from its Owings Mills facility and the establishment of an international commercial hub in Switzerland.

      Integration and acquisition costs

      For the three months to September 30, 2011 Shire recorded integration and acquisition costs of $5.3 million (Q3 2010: $5.8 million), which related to the acquisition and integration of ABH ($3.6 million) and the integration of Movetis ($1.7 million). In 2010 integration and acquisition costs solely related to the acquisition of Movetis.

      Interest expense

      For the three months to September 30, 2011 Shire incurred interest expense of $9.7 million (Q3 2010: $8.3 million). Interest expense principally relates to the coupon and amortization of issue costs on Shire's $1,100 million 2.75% convertible bonds due 2014.

      Other (expense)/income, net

                                       Q3 2011   Q3 2010
                                            $M        $M
          Other income, net (US GAAP)     15.6      0.8
          Gain on sale of investments    (23.5)       -
          Other (expense)/income, net
          (Non GAAP)                      (7.9)     0.8
      


      On a US GAAP basis, for the three months to September 30, 2011, Shire recognized $15.6 million of Other income, net (2010: $0.8 million) which includes a gain of $23.5 million arising on the disposal of substantially all of Shire's holding in Vertex (Shire received these shares as partial consideration for its investment in ViroChem Pharma, Inc following ViroChem Pharma, Inc being acquired by Vertex).

      Non GAAP Other expense, net in Q3 2011 (which excludes the gain on disposal of shares held in Vertex) included the impact of increased foreign exchange losses arising in the quarter, reflecting volatility in a number of currencies to which Shire has exposure.

      Taxation


      The Non GAAP effective tax rate in Q3 2011 of 25% was higher than Q3 2010 (24%) due to unfavourable changes in the profit mix in the quarter. We anticipate our Non GAAP effective tax rate to be between 22 and 24% for the full year.

      The US GAAP effective rate of tax in Q3 2011 of 27% was lower than Q3 2010 (35%) as Q3 2010 included the up-front payment to Acceleron and the intangible asset impairment charges for DAYTRANA. Taken together, these costs increased the US GAAP tax rate in Q3 2010 as they were either incurred in territories with tax rates lower than Shire's effective rate or in territories where the establishment of valuation allowances precluded the recognition of any tax benefit. Were the impact of these items excluded the effective tax rate in Q3 2010 would have been 24%.

      FINANCIAL INFORMATION

      TABLE OF CONTENTS

                                                    Page
       
          Unaudited US GAAP Consolidated
          Balance Sheets                              11
       
          Unaudited US GAAP Consolidated
          Statements of Income                        12
       
          Unaudited US GAAP Consolidated
          Statements of Cash Flows                    14
       
          Selected Notes to the Unaudited US
          GAAP Financial Statements
          (1) Earnings per share                      16
          (2) Analysis of revenues                    17
       
          Non GAAP reconciliation                     19
      


      Unaudited US GAAP financial position as of September 30, 2011
      Consolidated Balance Sheets

                                   September 30,  December 31,
                                            2011          2010
                                              $M            $M
          ASSETS
          Current assets:
          Cash and cash
          equivalents                      276.4         550.6
          Restricted cash                   21.0          26.8
          Accounts receivable, net         844.7         692.5
          Inventories                      325.9         260.0
          Deferred tax asset               179.0         182.0
          Prepaid expenses and
          other current assets             159.3         168.4
       
          Total current assets           1,806.3       1,880.3
       
          Non-current assets:
          Investments                       30.1         101.6
          Property, plant and
          equipment, net                   918.8         853.4
          Goodwill                         596.2         402.5
          Other intangible assets,
          net                            2,561.7       1,978.9
          Deferred tax asset               109.5         110.4
          Other non-current assets          43.0          60.5
       
          Total assets                   6,065.6       5,387.6
       
          LIABILITIES AND EQUITY
          Current liabilities:
          Accounts payable and
          accrued expenses               1,312.7       1,239.3
          Convertible bonds              1,100.0             -
          Deferred tax liability             4.3           4.4
          Other current
          liabilities                       56.0          49.6
       
          Total current
          liabilities                    2,473.0       1,293.3
       
          Non-current liabilities:
          Convertible bonds                    -       1,100.0
          Deferred tax liability           540.4         352.1
          Other non-current
          liabilities                       97.5         190.8
       
          Total liabilities              3,110.9       2,936.2
       
          Equity:
          Common stock of 5p par
          value; 1,000 million
          shares authorized; and
          562.5 million shares
          issued and outstanding
          (2010: 1,000 million
          shares authorized; and
          562.2 million shares
          issued and outstanding)           55.7          55.7
          Additional paid-in
          capital                        2,824.5       2,746.4
          Treasury stock: 12.5
          million shares (2010:
          14.0 million)                   (293.1)       (276.1)
          Accumulated other
          comprehensive income              88.5          85.7
          Retained
          earnings/(accumulated
          deficit)                         279.1        (160.3)
       
          Total equity                   2,954.7       2,451.4
       
          Total liabilities and
          equity                         6,065.6       5,387.6
      


      Unaudited US GAAP results for the three months and nine months to September 30, 2011
      Consolidated Statements of Income

                                                                       9 months
                             3 months to   3 months to   9 months to         to
                               September     September     September  September
                                     30,           30,           30,        30,
                                    2011          2010          2011       2010
                                      $M            $M            $M         $M
          Revenues:
          Product sales          1,018.4         794.3       2,901.0    2,276.8
          Royalties                 62.8          76.5         199.8      254.5
          Other revenues             4.9           3.5          20.4        8.6
          Total revenues         1,086.1         874.3       3,121.2    2,539.9
       
          Costs and
          expenses:
          Cost of product
          sales(1)                 166.5         112.7         434.7      333.7
          Research and
          development(1)           201.5         197.9         556.3      475.9
          Selling, general
          and
          administrative(1)        452.1         392.4       1,295.3    1,106.7
          Loss/(gain) on
          sale of product
          rights                     0.3             -           3.8       (4.1)
          Reorganization
          costs                      5.0           9.7          18.0       23.3
          Integration and
          acquisition costs          5.3           5.8           7.9        6.4
          Total operating
          expenses                 830.7         718.5       2,316.0    1,941.9
       
          Operating income         255.4         155.8         805.2      598.0
       
          Interest income            0.3           1.0           1.5        1.9
          Interest expense          (9.7)         (8.3)        (28.8)     (25.6)
          Other income, net         15.6           0.8          15.9        9.0
          Total other
          income/(expense),
          net                        6.2          (6.5)        (11.4)     (14.7)
       
          Income before
          income taxes and
          equity in
          earnings/(losses)
          of equity method
          investees                261.6         149.3         793.8      583.3
          Income taxes             (69.5)        (52.7)       (187.3)    (160.8)
          Equity in
          earnings/(losses)
          of equity method
          investees, net of
          taxes                      0.8          (0.3)           3.2       0.2
          Net income               192.9          96.3         609.7      422.7
      


      (1) Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.5 million for the three months to September 30, 2011 (2010: $0.4 million) and $1.4 million for the nine months to September 30, 2011 (2010: $1.3 million). R&D costs include intangible assets impairment charges of $16.0 million for the three months and nine months to September 30, 2011 (2010: $nil). SG&A costs include amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $46.4 million for the three months to September 30, 2011 (2010: $73.9 million) and $119.1 million for the nine months to September 30, 2011 (2010: $142.3 million).

      Unaudited US GAAP results for the three months and nine months to September 30, 2011
      Consolidated Statements of Income (continued)

                            3 months to   3 months to   9 months to   9 months to
                                            September     September     September
                          September 30,           30,           30,           30,
                                   2011          2010          2011          2010
       
          Earnings per
          ordinary share
          - basic                 35.0c         17.6c        110.6c         77.4c
       
          Earnings per
          ADS - basic            105.0c         52.8c        331.8c        232.2c
       
          Earnings per
          ordinary share
          - diluted               33.9c         17.3c        106.7c         76.0c
       
          Earnings per
          ADS - diluted          101.7c         51.9c        320.1c        228.0c
       
          Weighted
          average number
          of shares:
                               Millions      Millions      Millions      Millions
          Basic                   551.3         547.0         551.2         546.1
          Diluted                 593.8         556.7         595.0         589.7
      


      Unaudited US GAAP results for the three months and nine months to September 30, 2011
      Consolidated Statements of Cash Flows

                                             3 months to          9 months to
                                            September 30,        September 30,
                                             2011       2010     2011        2010
                                               $M         $M       $M          $M
          CASH FLOWS FROM OPERATING
          ACTIVITIES:
       
          Net income                        192.9       96.3    609.7       422.7
          Adjustments to reconcile net
          income to net cash provided by
          operating activities:
                      Depreciation and
                      amortization           80.0       60.0    212.3       189.2
                      Share based
                      compensation           19.8       17.5     54.7        44.2
                      Impairment of
                      intangible assets      16.0       42.7     16.0        42.7
                      Gain on sale of
                      non-current
                      investments           (23.5)         -    (23.5)      (11.1)
                      Loss/(gain) on sale
                      of product rights       0.3          -      3.8        (4.1)
                      Other                  11.7       (5.7)     5.9         5.2
          Movement in deferred taxes        (30.9)     (10.0)   (13.2)       48.7
          Equity in (earnings)/losses of
          equity method investees            (0.8)       0.3     (3.2)       (0.2)
          Changes in operating assets
          and liabilities:
                      Increase in
                      accounts receivable   (66.7)     (94.1)  (122.8)     (138.0)
                      (Decrease)/increase
                      in sales deduction
                      accrual               (19.9)      14.8     46.2       169.0
                      Increase in
                      inventory             (12.2)      (4.1)   (42.8)      (54.1)
                      Decrease/(increase)
                      in prepayments and
                      other assets           31.1       16.2     17.3       (67.0)
                      (Decrease)/increase
                      in accounts payable
                      and other
                      liabilities           (24.3)       2.3   (101.4)      (41.0)
          Returns on investment from
          joint venture                       5.2        5.8      5.2         5.8
          Net cash provided by operating
          activities(A)                     178.7      142.0    664.2       612.0
      


      Unaudited US GAAP results for the three months and nine months to September 30, 2011
      Consolidated Statements of Cash Flows (continued)

                                3 months to September     9 months to September
                                         30,                       30,
                                     2011          2010        2011          2010
                                       $M            $M          $M            $M
       
          CASH FLOWS FROM
          INVESTING
          ACTIVITIES:
       
          Movements in
          restricted cash             0.9       (553.0)         5.7       (547.0)
          Purchases of
          subsidiary
          undertakings, net
          of cash acquired           (3.8)           -       (723.5)           -
          Payments on foreign
          exchange contracts
          related to Movetis            -        (21.2)           -        (21.2)
          Purchases of
          non-current
          investments                (3.8)        (1.0)        (8.3)        (1.0)
          Purchases of
          property, plant and
          equipment ("PP&E")        (40.9)       (53.5)      (135.9)      (261.7)
          Purchases of
          intangible assets          (5.2)           -         (5.2)        (2.7)
          Proceeds from
          disposal of
          non-current
          investments and
          PP&E                       94.7            -         94.7          2.1
          Proceeds/deposits
          received on sales
          of product rights           1.9            -          8.8            -
          Returns of equity
          investments and
          proceeds from short
          term investments            0.1            -          1.7            -
          Net cash provided
          by/(used in)
          investing
          activities(B)              43.9       (628.7)      (762.0)      (831.5)
       
          CASH FLOWS FROM
          FINANCING
          ACTIVITIES:
       
          Proceeds from
          drawing of
          revolving credit
          facility                      -             -        30.0            -
          Repayment of
          revolving credit
          facility                  (30.0)             -      (30.0)           -
          Repayment of debt
          acquired with ABH             -             -       (13.1)           -
          Payment under
          building finance
          obligation                 (0.6)         (0.4)       (1.0)        (1.8)
          Extinguishment of
          building finance
          obligation                    -             -           -        (43.1)
          Tax benefit of
          stock based
          compensation                4.9           5.2        23.7          9.6
          Proceeds from
          exercise of options         0.1           0.2         0.9          2.1
          Payment of dividend           -             -       (60.5)       (49.8)
          Payments to acquire
          shares by Employee
          Share Ownership
          Trust ("ESOT")            (62.9)             -     (126.8)        (1.7)
          Net cash (used
          in)/provided by
          financing
          activities(C)             (88.5)           5.0     (176.8)       (84.7)
          Effect of foreign
          exchange rate
          changes on cash and
          cash equivalents
          (D)                        (2.3)         (7.5)        0.4         (1.4)
          Net
          increase/(decrease)
          in cash and cash
          equivalents(A) +(B)
          +(C) +(D)                 131.8        (489.2)     (274.2)      (305.6)
       
          Cash and cash
          equivalents at
          beginning of period       144.6         682.5       550.6        498.9
          Cash and cash
          equivalents at end
          of period                 276.4         193.3       276.4        193.3
      


      Unaudited US GAAP results for the three months and nine months to September 30, 2011

      Selected Notes to the Financial Statements

      (1)  Earnings Per Share ("EPS")

                         3 months to   3 months to   9 months to   9 months to
                           September     September     September     September
                                 30,           30,           30,           30,
                                2011          2010          2011          2010
                                  $M            $M            $M            $M
       
          Numerator for
          basic EPS            192.9          96.3         609.7         422.7
          Interest on
          convertible
          bonds, net of
          tax (1)                8.4             -          25.2          25.2
       
          Numerator for
          diluted EPS          201.3          96.3         634.9         447.9
       
          Weighted
          average
          number of
          shares:
                            Millions      Millions      Millions      Millions
          Basic(2)             551.3         547.0         551.2         546.1
          Effect of
          dilutive
          shares:
          Stock
          options(3)             9.0           9.7          10.4          10.4
          Convertible
          bonds 2.75%
          due 2014(4)           33.5             -          33.4          33.2
       
          Diluted              593.8         556.7         595.0         589.7
      


      1. For the three month period ended September 30, 2010 interest on the convertible bond has not been added back as the effect would be anti-dilutive.
      2. Excludes shares purchased by ESOT and presented by Shire as treasury stock.
      3. Calculated using the treasury stock method.
      4. Calculated using the "if converted" method.

      The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:

                           3 months to   3 months to   9 months to   9 months to
                             September     September     September     September
                                   30,           30,           30,           30,
                                  2011          2010          2011          2010
                              Millions      Millions      Millions      Millions
          Share awards(1)          3.2           3.6           3.9           8.9
          Convertible
          bonds 2.75% due
          2014(2)                    -          33.2             -             -
      


      1. Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire plc's average share price during the calculation period or (b) satisfaction of the required performance/market conditions cannot be measured until the conclusion of the performance period.
      2. For the three month period ended September 30, 2010 the ordinary shares underlying the convertible bonds have not been included in the calculation of the diluted weighted average number of shares, as the effect of their inclusion would be anti-dilutive.

      Unaudited US GAAP results for the three months to September 30, 2011

      Selected Notes to the Financial Statements

      (2)  Analysis of revenues

          3 months to
          September 30,         2011    2010     2011        2011
                                                    %  % of total
                                  $M      $M   change     Revenue
          Net product
          sales:
          Specialty Pharmaceutical
          ("SP")
          ADHD
          VYVANSE              199.7   151.2      32%         18%
          ADDERALL XR          149.9    99.7      50%         14%
          INTUNIV               56.1    37.3      50%          5%
          EQUASYM                5.1     5.7     -11%         <1%
          DAYTRANA                 -    14.7      n/a         n/a
                               410.8   308.6      33%         38%
          GI
          LIALDA/MEZAVANT       89.7    76.0      18%          8%
          PENTASA               55.9    57.1      -2%          5%
          RESOLOR                1.5       -      n/a         <1%
                               147.1   133.1      11%         14%
          General
          products
          FOSRENOL              40.5    45.2     -10%          4%
          XAGRID(R)             23.3    20.5      14%          2%
          CARBATROL(R)          12.3    20.3     -39%          1%
                                76.1    86.0     -12%          7%
       
          Other product
          sales                 24.0    25.3      -5%          2%
          Total SP
          product sales        658.0   553.0      19%         61%
       
          Human Genetic
          Therapies
          ("HGT")
          REPLAGAL             129.0    92.1      40%         12%
          ELAPRASE             109.6    96.8      13%         10%
          VPRIV                 64.6    49.5      31%          6%
          FIRAZYR                7.2     2.9     148%         <1%
          Total HGT
          product sales        310.4   241.3      29%         28%
       
          Regenerative
          Medicine ("RM")
          DERMAGRAFT            50.0       -      n/a          5%
          Total RM
          product sales         50.0       -      n/a          5%
       
          Total product
          sales              1,018.4   794.3      28%         94%
       
          Royalties:
          ADDERALL XR           22.9    18.0      27%          2%
          3TC and ZEFFIX        17.3    40.6     -57%          2%
          FOSRENOL              10.9     7.0      56%          1%
          Other                 11.7    10.9       7%          1%
          Total royalties       62.8    76.5     -18%          6%
       
          Other revenues         4.9     3.5      40%         <1%
       
          Total Revenues     1,086.1   874.3      24%        100%
      


      Unaudited US GAAP results for the nine months to September 30, 2011

      Selected Notes to the Financial Statements

      (2)  Analysis of revenues

          9 months to
          September 30,       2011      2010      2011        2011
                                                     %  % of total
                                $M        $M    change     Revenue
          Net product
          sales:
          SP
          ADHD
          VYVANSE            587.9     453.6       30%         19%
          ADDERALL XR        408.0     271.9       50%         13%
          INTUNIV            157.6     123.0       28%          5%
          EQUASYM             15.6      16.3       -4%         <1%
          DAYTRANA               -      49.4       n/a         n/a
                           1,169.1     914.2       28%         37%
          GI
          LIALDA/MEZAVANT    276.0     209.2       32%          9%
          PENTASA            186.2     175.9        6%          6%
          RESOLOR              4.0         -       n/a         <1%
                             466.2     385.1       21%         15%
          General
          products
          FOSRENOL           127.0     137.4       -8%          4%
          XAGRID              69.2      65.4        6%          2%
          CARBATROL           45.6      63.4      -28%          2%
                             241.8     266.2       -9%          8%
       
          Other product
          sales               71.7      80.2      -11%          2%
          Total SP
          product sales    1,948.8   1,645.7       18%         62%
       
          HGT
          REPLAGAL           354.3     242.0       46%         11%
          ELAPRASE           340.9     297.4       15%         11%
          VPRIV              186.9      84.0      123%          6%
          FIRAZYR             18.1       7.7      135%          1%
          Total HGT
          product sales      900.2     631.1       43%         29%
       
          RM
          DERMAGRAFT          52.0         -       n/a          2%
          Total RM
          product sales       52.0         -       n/a          2%
       
          Total product
          sales            2,901.0   2,276.8       27%         93%
       
          Royalties:
          ADDERALL XR         66.6      86.3      -23%          2%
          3TC and ZEFFIX      64.1     115.3      -44%          2%
          FOSRENOL            31.4      18.0       74%          1%
          Other               37.7      34.9        8%          1%
          Total royalties    199.8     254.5      -21%          6%
       
          Other revenues      20.4       8.6      137%          1%
       
          Total Revenues   3,121.2   2,539.9       23%        100%
      


      Unaudited results for the three months to September 30, 2011

      Non GAAP reconciliation

                           US GAAP             Adjustments                 Non GAAP
                                        Acquisitions Divestments,
                             Amortization   &      reorganizations
                           Sept & asset integration & discontinued Reclas September
          3 months to,      30, impair   activities  operations    -sify      30,
                           2011 -ments                           depreciation 2011
                                   (a)      (b)          (c)      (d)
                           $M      $M       $M           $M       $M        $M
          Total revenues   1,086.1     -        -            -        -    1,086.1
       
          Costs and
          expenses:
          Cost of product
          sales              166.5     -     (9.0)       (3.4)     (8.6)     145.5
          Research and
          development        201.5 (16.0)       -           -      (5.6)     179.9
          Selling, general
          and
          administrative     452.1 (46.4)       -                 (16.7)     389.0
          Loss on sale of
          product rights       0.3     -        -        (0.3)        -          -
          Reorganization
          costs                5.0     -        -        (5.0)        -          -
          Integration and
          acquisition costs    5.3     -     (5.3)          -         -          -
          Depreciation           -     -        -           -      30.9       30.9
          Total operating
          expenses           830.7 (62.4)   (14.3)       (8.7)        -      745.3
       
          Operating income   255.4  62.4     14.3         8.7         -      340.8
       
          Interest income      0.3     -        -           -         -        0.3
          Interest expense    (9.7)    -        -           -         -       (9.7)
          Other
          income/(expense),
          net                 15.6     -        -       (23.5)        -       (7.9)
          Total other
          income/(expense),
          net                  6.2     -        -       (23.5)        -      (17.3)
          Income before
          income taxes and
          equity in
          earnings of
          equity method
          investees          261.6  62.4     14.3       (14.8)        -      323.5
          Income taxes       (69.5)(16.4)    (2.9)        9.2                (79.6)
          Equity in
          earnings of
          equity method
          investees, net of
          tax                  0.8     -        -           -         -        0.8
          Net income         192.9  46.0     11.4        (5.6)        -      244.7
          Impact of
          convertible debt,
          net of tax           8.4     -        -               -     -        8.4
          Numerator for
          diluted EPS        201.3  46.0     11.4           (5.6)     -      253.1
          Weighted average
          number of shares
          (millions) -
          diluted            593.8     -        -               -     -      593.8
          Diluted earnings
          per ADS            101.7c 23.2c     5.8c          (2.8c)    -      127.9c
      


      The following items are included in Adjustments:

      a)Amortization and asset impairments: Impairment of intangible assets ($16.0 million), amortization of intangible assets relating to intellectual property rights acquired ($46.4 million), and tax effect of adjustments;

      b)Acquisition and integration activities: Unwind of ABH inventory step-up ($9.0 million), costs associated with the acquisition and integration of ABH ($3.6 million) and integration of Movetis ($1.7 million), and tax effect of adjustments;

      c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($2.2 million) and dual running costs ($1.2 million) on the transfer of manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA contingent consideration to fair value ($0.3 million), reorganization costs ($5.0 million) on the transfer of manufacturing from Owings Mills to a third party and establishment of an international commercial hub in Switzerland, gain on disposal of investment in Vertex ($23.5 million), and tax effect of adjustments; and

      d)Depreciation: Depreciation of $30.9 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


      Unaudited results for the three months to September 30, 2010

      Non GAAP reconciliation

                       US GAAP                 Adjustments          Non GAAP
      
                                         Acquis   Divestments,
                                 Amorti  itions & reorgan
                       September -zation integr  -izations & Reclas September
          3 months to,    30,   & asset  -ation  discontinued -sify    30,
                         2010  impairments activ operations   deprec  2010
                                          -ities              -iation
                                            (a)     (b)       (c)      (d)
                          $M        $M      $M      $M        $M        $M
          Total revenues 874.3       -       -       -         -      874.3
       
          Costs and
          expenses:
          Cost of
          product sales  112.7       -       -    (7.3)     (2.3)     103.1
          Research and
          development    197.9       -   (45.0)      -      (4.4)     148.5
          Selling,
          general and
          administrative 392.4   (73.9)      -       -     (16.1)     302.4
          Reorganization
          costs            9.7       -       -    (9.7)        -          -
          Integration
          and
          acquisition
          costs            5.8       -    (5.8)      -         -          -
          Depreciation       -       -       -       -      22.8       22.8
          Total
          operating
          expenses       718.5   (73.9)  (50.8)  (17.0)        -      576.8
       
          Operating
          income         155.8    73.9    50.8    17.0         -      297.5
       
          Interest
          income           1.0       -       -       -         -        1.0
          Interest
          expense         (8.3)      -       -       -         -       (8.3)
          Other income,
          net              0.8       -       -       -         -        0.8
          Total other
          expense, net    (6.5)      -       -       -         -       (6.5)
          Income before
          income taxes
          and equity in
          losses of
          equity method
          investees      149.3    73.9    50.8    17.0         -      291.0
          Income taxes   (52.7)  (10.1)   (3.5)   (4.1)        -      (70.4)
          Equity in
          losses of
          equity method
          investees, net
          of tax          (0.3)      -       -       -         -       (0.3)
          Net income      96.3    63.8    47.3    12.9         -      220.3
          Impact of
          convertible
          debt, net of
          tax (1)            -     8.4       -       -         -        8.4
          Numerator for
          diluted EPS     96.3    72.2    47.3    12.9         -      228.7
          Weighted
          average number
          of shares
          (millions) -
          diluted        556.7    33.2       -       -         -      589.9
          Diluted
          earnings per
          ADS             51.9c   33.8c   24.0c    6.6c        -      116.3c
      


      (1)    The impact of convertible debt, net of tax has a dilutive effect on Non GAAP basis.

      The following items are included in Adjustments:

      a)Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($31.2 million), impairment charges to record DAYTRANA assets at fair value less costs to sell ($42.7 million) and tax effect of adjustments;

      b)Acquisitions and integration activities: Upfront payment to Acceleron ($45.0 million), acquisition costs are principally costs associated with the acquisition of Movetis ($5.8 million) and tax effect of adjustments;

      c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($6.2 million) and dual running costs ($1.1 million) on the transfer of manufacturing from Owings Mills and reorganization costs ($9.7 million) on the transfer of manufacturing from Owings Mills and establishment of an international commercial hub in Switzerland, and tax effect of adjustments; and

      d)Depreciation: Depreciation of $22.8 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


      Unaudited results for the nine months to September 30, 2011

      Non GAAP reconciliation

                       US GAAP                 Adjustments          Non GAAP
      
                                         Acquis   Divestments,
                                 Amorti  itions & reorgan
                       September -zation integr  -izations & Reclas September
          9 months to,    30,   & asset  -ation  discontinued -sify    30,
                         2011  impairments activ operations   deprec  2011
                                          -ities              -iation
                                               (a)      (b)       (c)      (d)
                              $M       $M      $M        $M       $M        $M
          Total revenues   3,121.2      -       -         -        -   3,121.2
          Costs and
          expenses:
          Cost of product
          sales              434.7      -    (9.0)     (9.0)   (22.4)     394.3
          Research and
          development        556.3  (16.0)      -         -    (16.4)     523.9
          Selling, general
          and
          administrative   1,295.3 (119.1)      -         -    (46.4)   1,129.8
          Loss on sale of
          product rights       3.8      -       -      (3.8)       -          -
          Reorganization
          costs               18.0      -       -     (18.0)       -          -
          Integration &
          acquisition costs    7.9      -    (7.9)        -        -          -
          Depreciation           -      -       -         -     85.2       85.2
          Total operating
          expenses         2,316.0 (135.1)  (16.9)    (30.8)       -    2,133.2
       
          Operating income   805.2  135.1    16.9      30.8        -      988.0
       
          Interest income      1.5      -       -         -        -        1.5
          Interest expense   (28.8)     -       -         -        -      (28.8)
          Other
          income/(expense),
          net                 15.9    2.4       -     (23.5)       -       (5.2)
          Total other
          expense, net       (11.4)   2.4       -     (23.5)       -      (32.5)
          Income before
          income taxes and
          equity in
          earnings of
          equity method
          investees          793.8  137.5    16.9       7.3        -      955.5
          Income taxes      (187.3) (35.6)   (4.2)      4.5              (222.6)
          Equity in
          earnings of
          equity method
          investees, net of
          tax                  3.2      -       -         -        -        3.2
          Net income         609.7  101.9    12.7      11.8        -      736.1
          Impact of
          convertible debt,
          net of tax          25.2      -       -         -        -       25.2
          Numerator for
          diluted EPS        634.9  101.9    12.7      11.8        -      761.3
          Weighted average
          number of shares
          (millions) -
          diluted            595.0      -       -         -        -      595.0
          Diluted earnings
          per ADS            320.1c  51.4c    6.4c      5.9c       -      383.8c
      


      The following items are included in Adjustments:

      a)Amortization and asset impairments: Impairment of intangible assets ($16.0 million), amortization of intangible assets relating to intellectual property rights acquired ($119.1 million), impairment of available for sale securities ($2.4 million), and tax effect of adjustments;

      b)Acquisitions and integration activities: Unwind of ABH inventory step-up ($9.0 million), costs associated with acquisition and integration of ABH ($10.5 million) and integration of Movetis ($5.6 million), less adjustment to contingent consideration payable for EQUASYM ($8.2 million), and tax effect of adjustments;

      c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($6.6 million) and dual running costs ($2.4 million) on the transfer of manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA contingent consideration to fair value ($3.8 million), reorganization costs ($18.0 million) on the transfer of manufacturing from Owings Mills to a third party and the establishment of an international commercial hub in Switzerland, gain on disposal of investment in Vertex ($23.5 million), and tax effect of adjustments; and

      d)Depreciation: Depreciation of $85.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


      Unaudited results for the nine months to September 30, 2010

      Non GAAP reconciliation

                       US GAAP                 Adjustments          Non GAAP
      
                                         Acquis   Divestments,
                                 Amorti  itions & reorgan
                       September -zation integr  -izations & Reclas September
          9 months to,    30,   & asset  -ation  discontinued -sify    30,
                         2010  impairments activ operations   deprec  2010
                                          -ities              -iation
                                            (a)       (b)       (c)      (d)
                           $M         $M    $M        $M        $M        $M
          Total revenues  2,539.9      -     -        -          -   2,539.9
          Costs and
          expenses:
          Cost of product
          sales             333.7      -     -    (21.9)      (8.6)    303.2
          Research and
          development       475.9      - (45.0)       -      (11.6)    419.3
          Selling, general
          and
          administrative  1,106.7 (142.3)    -        -      (49.0)    915.4
          Gain on sale of
          product rights     (4.1)     -     -      4.1          -         -
          Reorganization
          costs              23.3      -     -    (23.3)         -         -
          Integration and
          acquisition costs   6.4      -  (6.4)       -          -         -
          Depreciation          -      -     -        -       69.2      69.2
          Total operating
          expenses        1,941.9 (142.3)(51.4)   (41.1)         -   1,707.1
       
          Operating income  598.0  142.3  51.4     41.1          -     832.8
       
          Interest income     1.9      -     -        -          -       1.9
          Interest expense  (25.6)     -     -        -          -     (25.6)
          Other
          income/(expense),
          net                 9.0      -     -    (11.1)         -      (2.1)
          Total other
          expense, net      (14.7)     -     -    (11.1)         -     (25.8)
          Income before
          income taxes and
          equity in
          earnings of
          equity method
          investees         583.3  142.3  51.4     30.0          -     807.0
          Income taxes     (160.8) (29.4) (3.6)    (9.1)         -    (202.9)
          Equity in
          earnings of
          equity method
          investees, net of
          tax                 0.2      -     -        -          -        0.2
          Net income        422.7  112.9  47.8     20.9          -      604.3
          Impact of
          convertible debt,
          net of tax         25.2      -     -        -          -       25.2
          Numerator for
          diluted EPS       447.9  112.9  47.8     20.9          -      629.5
          Weighted average
          number of shares
          (millions) -
          diluted           589.7      -     -        -          -      589.7
          Diluted earnings
          per ADS           228.0c  57.3c 24.3c    10.6c         -      320.2c
      


      The following items are included in Adjustments:

      a)Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($99.6 million), impairment charges to record DAYTRANA assets at fair value less costs to sell ($42.7 million) and tax effect of adjustments;

      b)Acquisitions and integration activities: Up-front payment to Acceleron ($45.0 million), acquisition costs are principally costs associated with the acquisition of Movetis ($6.4 million) and tax effect of adjustments;

      c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($18.3 million) and dual running costs ($3.6 million) on the transfer of manufacturing from Owings Mills, gain on sale of product rights relating to the disposal of non core products to Laboratorios Almirall S.A. ($4.1 million), reorganization costs ($23.3 million) on the transfer of manufacturing from Owings Mills and the establishment of an international commercial hub in Switzerland, gain on disposal of the investment in Virochem ($11.1 million) and tax effect of adjustments; and

      d)Depreciation: Depreciation of $69.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


      Unaudited results for the three months and nine months to September 30, 2011

      Non GAAP reconciliation

      The following table reconciles US GAAP net cash provided by operating activities to Non GAAP cash generation:

                        3 months to September 30,    9 months to September 30,
                               2011           2010         2011            2010
                                 $M             $M           $M              $M
          Net cash
          provided by
          operating
          activities          178.7          142.0        664.2           612.0
          Tax and
          interest
          payments,
          net                 117.2           83.6        280.0           301.6
          Payments for
          acquired and
          in-licensed
          products                -           45.0            -            45.0
          Non GAAP
          cash
          generation          295.9          270.6        944.2           958.6
      


      The following table reconciles US GAAP net cash provided by operating activities to Non GAAP free cashflow:

                                 3 months to September     9 months to September
                                         30,                       30,
                                       2011       2010        2011          2010
                                         $M        $M          $M            $M
          Net cash provided by
          operating activities       178.7       142.0       664.2         612.0
          Capital expenditure (1)    (40.9)      (53.5)     (135.9)       (139.7)
          Non GAAP free cash flow    137.8        88.5       528.3         472.3
      


      (1) Capital expenditure for the nine months ended September 30, 2010 excludes capital expenditure relating to the acquisition of Lexington Technology Park.

      Non GAAP net debt comprises:

                             September 30,  December 31,
                                      2011          2010
                                        $M            $M
          Cash and cash
          equivalents                276.4         550.6
          Restricted cash             21.0          26.8
       
          Convertible bonds       (1,100.0)     (1,100.0)
          Building finance
          obligation                  (8.3)         (8.4)
          Non GAAP net debt         (810.9)       (531.0)
      


      NOTES TO EDITORS

      THE "SAFEHARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

      Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicines products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission.

      Non GAAP Measures

      This press release contains financial measures not prepared in accordance with US GAAP.)These measures are referred to as "Non GAAP" measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effectivetax rate on Non GAAP income before income taxes and earnings of equity method investees ("Effective tax rate on Non GAAP income"); Non GAAP cost of product sales; Non GAAP research and development; Non GAAP selling, general and administrative; Non GAAP other income; Non GAAP cash generation; Non GAAP free cashflow and Non GAAP net debt. These Non GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire's business.

      These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of Shire's performance to historical results and to competitors' results.)Shire's Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire's executive directors.

      The Non GAAP measures are presented in this press release as Shire's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, Shire's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.

      These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.

      Where applicable the following items, including their tax effect, have been excluded from both 2011 and 2010 Non GAAP earnings, and from our 2011 Outlook:

      Amortization and asset impairments:

      • Intangible asset amortization and impairment charges; and
      • Other than temporary impairment of investments.

      Acquisitions and integration activities:

      • Upfront payments and milestones in respect of in-licensed and acquired products;
      • Costs associated with acquisitions, including transaction costs, fair value adjustments on contingent consideration and acquired inventory;
      • Costs associated with the integration of companies; and
      • Noncontrolling interests in consolidated variable interest entities.

      Divestments, re-organizations and discontinued operations:

      • Gains and losses on the sale of non-core assets;
      • Costs associated with restructuring and re-organization activities;
      • Termination costs; and
      • Income/(losses) from discontinued operations.

      Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2010 and 2011 Non GAAP earnings.

      Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments.

      Free cashflow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business.

      A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented on pages 19 to 23.

      Sales growth at CER, which is a Non GAAP measure, is computed by restating 2011 results using average 2010 foreign exchange rates for the relevant period.

      Average exchange rates for the nine months to September 30, 2011 were $1.61:£1.00 and $1.41:€1.00 (2010: $1.54:£1.00 and $1.32:€1.00). Average exchange rates for Q3 2011 were $1.61:£1.00 and $1.41:€1.00 (2010: $1.55:£1.00 and $1.29:€1.00).

      TRADEMARKS

      All trademarks designated ® and ™ used in this press release are trademarks of Shire plc or companies within the Shire group except for 3TC® and ZEFFIX® which are trademarks of GSK, PENTASA® which is a registered trademark of FERRING B.V., CONCERTA® which is a trademark of ALZA Corporation, FABRAZYME® and CEREZYME® which are trademarks of GENZYME Therapeutic Products Limited Partnership and DAYTRANA® which is a trade mark of Noven Pharmaceuticals Inc. Certain trademarks of Shire plc or companies within the Shire group are set out in Shire's Annual Report on Form 10-K for the year ended December 31, 2010 and the Quarterly Report on Form 10-Q for the three months ended June 30, 2011.

      For further information please contact:

      Investor Relations
      Eric Rojas, erojas@shire.com, +1-781-482-0999
      Sarah Elton-Farr, seltonfarr@shire.com, +44-1256-894-157
      Media

      Jessica Mann (Corporate), jmann@shire.com, +44-1256-894-280
      Matthew Cabrey (Specialty Pharma), mcabrey@shire.com, +1-484-595-8248
      Jessica Cotrone (Human Genetic Therapies), jcotrone@shire.com, +1-781-482-9538
      Lindsey Hart (Regenerative Medicine), lhart@abh.com, +1-615-250-3311

      Dial in details for the live conference call for investors 14:00 BST/9:00 EDT on October 28, 2011:

      UK dial in: 0800-077-8492 or 0844-335-0351
      US dial in: 1-866-804-8688 or 1-718-3541175
      International dial in: +44-208-996-3900
      Password/Conf ID: 280117
      Live Webcast: http://www.shire.com/shireplc/en/investors


      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.